Trial Information
Inclusion Criteria:
- Histologically confirmed, locally advanced, recurrent or metastatic colorectal cancer
- ECOG 0 or 1
- Measurable disease
Exclusion Criteria:
- Prior first line therapy for advanced disease
- Significant bulk of metastatic disease or rapid progression
- If prior adjuvant therapy, relapse within 6 months of a 5-FU based regimen or 12
months of an oxaliplatin based regimen
Other protocol-defined inclusion/exclusion criteria may apply
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Tumour response as assessed by CT scan and RESIST
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Novartis Pharmaceuticals
Investigator Role:
Study Director
Investigator Affiliation:
Novartis Pharmaceuticals
Authority:
Australia: Department of Health and Ageing Therapeutic Goods Administration
Study ID:
CSTI571BAU14
NCT ID:
NCT01271166
Start Date:
October 2007
Completion Date:
Related Keywords:
- Advanced Colorectal Cancer
- Colorectal,
- Cancer
- Colorectal Neoplasms